Residual risk reduction opportunities in patients with chronic coronary syndrome. Role of dual pathway inhibition-Reference-Cited by-同舟云学术

Residual risk reduction opportunities in patients with chronic coronary syndrome. Role of dual pathway inhibition

Published:2020-07-02 Issue:7 Volume:13 Page:695-706
ISSN:1751-2433
Container-title:Expert Review of Clinical Pharmacology
language:en
Short-container-title:Expert Review of Clinical Pharmacology

Author:

González-Juanatey José R.¹,Almendro-Delia Manuel²,Cosín-Sales Juan³,Bellmunt-Montoya Sergi⁴,Gómez-Doblas Juan José⁵,Riambau Vincent⁶,García-Moll Xavier⁷,García-Alegría Javier⁸,Hernández José Luis⁹,Lozano Francisco S.¹⁰,Suarez Fernández Carmen¹¹

Affiliation:

1. Cardiology and Intensive Cardiac Care Department, CIBERCV, University Hospital Santiago de Compostela, Santiago de Compostela, Spain

2. Intensive Cardiovascular Care Unit, Cardiovascular Clinical Trials & Translational Research Unit, Cardiology and Cardiovascular Surgery Division, Virgen Macarena University Hospital, Seville, Spain

3. Cardiology Department, Hospital Arnau de Vilanova, Facultad de Medicina, Universidad CEU-Cardenal Herrena, Valencia, Spain

4. Vascular Surgery Department, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain

5. Cardiology Department, Hospital Universitario Virgen de la Victoria, Malaga, Spain

6. Vascular Surgery Division, CardioVascular Institute Hospital Clinic University of Barcelona, Barcelona, Spain

7. Cardiology Department, Hospital Sant Pau, Barcelona, Spain

8. Department of Medicine, Hospital Costa del Sol, Marbella, Spain

9. Internal Medicine Department, Hospital Marqués de Valdecilla-IDIVAL, Universidad de Cantabria, Santander, Spain

10. Department of Vascular Surgery, Hospital Clínico de Salamanca, Salamanca, Spain

11. Internal Medicine Department, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Madrid, Spain

Funder

Bayer Hispania

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17512433.2020.1772056

Reference77 articles.

1. Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association

2. Cardiovascular disease statistics from the European atlas: inequalities between high- and middle-income member countries of the ESC

3. Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry

4. The Impact of the Aging Population on Coronary Heart Disease in the United States

5. Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980–2000

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Angiopoietin-like Proteins and Lipoprotein Lipase: The Waltz Partners That Govern Triglyceride-Rich Lipoprotein Metabolism? Impact on Atherogenesis, Dietary Interventions, and Emerging Therapies;Journal of Clinical Medicine;2024-09-04

2. The chylomicron saga: time to focus on postprandial metabolism;Frontiers in Endocrinology;2024-01-18

3. Triglyceride-Rich Lipoprotein Metabolism: Key Regulators of Their Flux;Journal of Clinical Medicine;2023-06-29

4. Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines;Cardiology Journal;2020-12-31